Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Prior treatment

• Previous treatment with C5 inhibitors
• Last rituximab infusion performed \< 6 months before T-4 (Enrolment)
• Last infusion with FcRn blockers performed \< 3 months before T-4 (Enrollment)
• Previous or current participation to other interventional studies

Other illness

• Hypersensitivity to the active substance or to any of the excipients of the study product

Other

• Patient unable to understand and sign the informed consent
• Patient for whom the study product is contraindicated according to SmPC
• Pregnant or lactating or planning a pregnancy during the study
• Patient who plan to relocate during the study
• Patient who are unsure of following the visit schedule
• Patient unable to complete questionnaires

• Diagnosis of MG confirmed by:
  • History of a positive serologic test for anti-AChR antibodies, and
  • One of the following:
  • History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation
  • History of positive anticholinesterase test (e.g., edrophonium chloride test); or
  • Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician
• Disease duration from MG onset ≤ 3 years before T-4 (Enrolment);
• MGFA class IIb to IV;
• Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria
• Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.